{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:11:50Z","timestamp":1779120710451,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40262-026-01631-7","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:17:10Z","timestamp":1774973830000},"page":"747-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct05166421","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9684-9942","authenticated-orcid":false,"given":"Huixia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Sadow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Baronio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella Nadia","family":"Tullio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitalina","family":"Dzutseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecil Chi-Keung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Kiazand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Jah","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"1631_CR1","unstructured":"European Medicines Agency. Assessment report Evusheld, 24 March 2022. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/evusheld-epar-public-assessment-report_en.pdf. Accessed 10 Jan 2025."},{"key":"1631_CR2","unstructured":"US Food and Drug Administration. Emergency use authorization (EUA) for EVUSHELD center for drug Evaluation and research review memorandum. 2023. https:\/\/www.fda.gov\/media\/165226\/download. Accessed 8 Nov 2024."},{"issue":"33","key":"1631_CR3","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514\u201324. https:\/\/doi.org\/10.1074\/jbc.M604292200.","journal-title":"J Biol Chem"},{"issue":"635","key":"1631_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"YM Loo","year":"2022","unstructured":"Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022;14(635):eabl8124. https:\/\/doi.org\/10.1126\/scitranslmed.abl8124.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1631_CR5","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/jiad014","volume":"227","author":"P Forte-Soto","year":"2023","unstructured":"Forte-Soto P, Albayaty M, Brooks D, et al. Safety, tolerability and pharmacokinetics of half-life extended severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (tixagevimab\u2013cilgavimab) in healthy adults. J Infect Dis. 2023;227(10):1153\u201363. https:\/\/doi.org\/10.1093\/infdis\/jiad014.","journal-title":"J Infect Dis"},{"key":"1631_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jiac.2023.07.014","volume":"29","author":"H Okada","year":"2023","unstructured":"Okada H, Ishikawa K, Itoh Y, et al. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab\/cilgavimab) in healthy Japanese adults. J Infect Chemother. 2023;29:1061\u20137. https:\/\/doi.org\/10.1016\/j.jiac.2023.07.014.","journal-title":"J Infect Chemother"},{"key":"1631_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01587-23","volume":"68","author":"LE Clegg","year":"2024","unstructured":"Clegg LE, Stepanov O, Schmidt H, et al. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab\/cilgavimab) in the prophylaxis and treatment of COVID-19. Antimicrob Agents Chemother. 2024;68:e0158723. https:\/\/doi.org\/10.1128\/aac.01587-23.","journal-title":"Antimicrob Agents Chemother"},{"issue":"43","key":"1631_CR8","doi-asserted-by":"publisher","first-page":"14835","DOI":"10.1021\/acs.analchem.2c01320","volume":"94","author":"R Mu","year":"2022","unstructured":"Mu R, Huang Y, Bouquet J, et al. Multiplex hybrid antigen-capture LC-MRM quantification in sera and nasal lining fluid of AZD7442, a SARS-CoV-2-targeting antibody combination. Anal Chem. 2022;94(43):14835\u201345. https:\/\/doi.org\/10.1021\/acs.analchem.2c01320.","journal-title":"Anal Chem"},{"issue":"6","key":"1631_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s40121-024-00970-x","volume":"13","author":"MJ Levin","year":"2024","unstructured":"Levin MJ, Ustianowski A, De Wit S, et al. Efficacy, safety, and pharmacokinetics of AZD7442 (tixagevimab\/cilgavimab) for prevention of symptomatic COVID-19: 15-month final analysis of the PROVENT and STORM CHASER trials. Infect Dis Ther. 2024;13(6):1253\u201368. https:\/\/doi.org\/10.1007\/s40121-024-00970-x.","journal-title":"Infect Dis Ther"},{"issue":"23","key":"1631_CR10","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386(23):2188\u2013200. https:\/\/doi.org\/10.1056\/NEJMoa2116620.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1631_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.2119","volume":"12","author":"A Ustianowski","year":"2025","unstructured":"Ustianowski A, Levin MJ, De Wit S, et al. P-1960. Safety and pharmacokinetics of long-acting SARS-CoV-2 antibodies tixagevimab\/cilgavimab (AZD7442) are consistent after repeat dosing: results from the PROVENT substudy. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.2119. https:\/\/doi.org\/10.1093\/ofid\/ofae631.2119.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1631_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40121-024-00931-4","volume":"13","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs FDR, Montgomery H, Padilla F, et al. Safety, efficacy and pharmacokinetics of AZD7442 (tixagevimab\/cilgavimab) for treatment of mild-to-moderate COVID-19: 15-month final analysis of the TACKLE trial. Infect Dis Ther. 2024;13(3):521\u201333. https:\/\/doi.org\/10.1007\/s40121-024-00931-4.","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"1631_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.2128","volume":"12","author":"T Cohen","year":"2025","unstructured":"Cohen T, Rensoli Valzquez M, Munthali C, et al. P-1969. Safety, immunogenicity, and pharmacokinetics of repeat dosing with AZD7442 (tixagevimab\/cilgavimab): final analysis of the ENDURE phase 2, dose-ranging study in immunocompromised participants. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.2128. https:\/\/doi.org\/10.1093\/ofid\/ofae631.2128.","journal-title":"Open Forum Infect Dis"},{"key":"1631_CR14","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Bioavailability studies submitted in NDAs or INDs\u2014general considerations. Guidance for Industry. 2022. https:\/\/www.fda.gov\/media\/121311\/download. Accessed 18 Nov 2025."},{"key":"1631_CR15","unstructured":"US Food and Drug Administration. Draft guidance on warfarin sodium. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Warfarin_Sodium_tab_09218_RC12-12.pdf. Accessed 18 Nov 2025."},{"key":"1631_CR16","unstructured":"US Food and Drug Administration. Draft guidance on lusutrombopag. 2020 (updated October 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_210923.pdf. Accessed 18 Nov 2025."},{"issue":"12","key":"1631_CR17","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3109\/00498254.2014.941963","volume":"44","author":"K Haraya","year":"2014","unstructured":"Haraya K, Tachibana T, Nanami M, Ishigai M. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica. 2014;44(12):1127\u201334. https:\/\/doi.org\/10.3109\/00498254.2014.941963.","journal-title":"Xenobiotica"},{"issue":"12","key":"1631_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/jcph.2322","volume":"63","author":"YF Wen","year":"2023","unstructured":"Wen YF, Ji P, Schrieber SJ, et al. Evaluation of truncated AUC as an alternative measure to assess pharmacokinetic comparability in bridging biologic-device using prefilled syringes and autoinjectors. J Clin Pharmacol. 2023;63(12):1417\u201329. https:\/\/doi.org\/10.1002\/jcph.2322.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01631-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:50:44Z","timestamp":1779119444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01631-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01631-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Huixia Zhang, Weifeng Tang, Samuel Sadow, Antonella Nadia Tullio, Lauren Hirao, Vitalina Dzutseva, Lee-Jah Chang, Taylor S. Cohen and Michael Gibbs are employees of AstraZeneca and may or may not hold stock in AstraZeneca. Roberta Baronio was previously a consultant for AstraZeneca. Cecil Chi-Keung Chen and Alexandre Kiazand were employees of AstraZeneca at the time of this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Before the start of the clinical study, the clinical study protocol, informed consent form, and other relevant documents were submitted to the regulatory authority and institutional review boards for review and approval, in accordance with local regulatory procedures. The protocol was approved by institutional review board Advarra, 6100 Meriweather Drive, Columbia, MD 21044 on 02 November 2021. The study was performed in accordance with ethical principles that had their origin in the Declaration of Helsinki and were consistent with the International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines and the AstraZeneca policy on Bioethics and Human Biological Samples.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent to participate in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at\n                      \n                      . Data for studies directly listed on Vivli can be requested through Vivli at\n                      \n                      . Data for studies not listed on Vivli could be requested through Vivli at\n                      \n                      . AstraZeneca Vivli member page is also available outlining further details:\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: TSC, L-JC and MG; Methodology: HZ, WT, RB, SS, ANT, LH, VD, CC-KC, AK, L-JC, TSC, MG; Formal analysis and investigation: HZ, WT, RB, SS, ANT, LH, VD, CC-KC, AK, L-JC, TSC, MG; Writing \u2013 original draft preparation: HZ, WT, RB, SS, ANT, LH, and MG; Writing \u2013 review and editing: HZ, WT, RB, SS, ANT, LH, VD, CC-KC, AK, L-JC, TSC, MG; Funding acquisition: TSC and L-JC; Resources: TSC, L-JC, and MG; Supervision: AK, TSC, L-JC, and MG. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}